Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

NCT Number	NCT06975787
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Lupus Nephritis (LN)
Enrollment	90 participants
Start Date	2025-12-22
Primary Completion	2029-09-10 (estimated)
Study Completion	2029-09-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-13